Literature DB >> 1832597

Accelerated diabetes in non-obese diabetic (NOD) mice differing in incidence of spontaneous disease.

A G Baxter1, T E Mandel.   

Abstract

The NOD mouse is an established model of autoimmune diabetes mellitus. Various lines of NOD mice differ in their incidence of spontaneous diabetes, e.g. 93% of female NOD/Lt mice compared with 46% of female NOD/Wehi mice develop diabetes by 250 days. These two lines were studied under conditions which greatly accelerate the onset of hyperglycaemia. It was hoped that their responses to these manipulations would reveal characteristic differences which would increase our understanding of diabetes resistance in the low incidence NOD/Wehi line. One dose of 300 mg/kg of cyclophosphamide (CP) produced hyperglycaemia in 50% of NOD mice within 2 weeks in both lines. They were also equally susceptible to diabetes induced by splenocyte transfer at 21 days of age from prediabetic 150-day-old NOD/Lt or NOD/Wehi females. Five daily 40 mg/kg doses of streptozotocin (STZ) resulted in a severity of diabetes in the NOD mice greater than in C57BL or SJL/mice. While the incidence and severity of diabetes induced in the two NOD lines were similar, this appeared to be principally due to sensitivity to the toxic effects of STZ rather than its ability to exacerbate autoimmune beta cell destruction. It has previously been shown that it is possible to prevent diabetes in susceptible NOD mice with simple, relatively benign therapies and here we show that it is possible to induce diabetes in resistant animals at a rate indistinguishable from fully predisposed individuals. It therefore appears that the prediabetic NOD mouse is poised in an immunologically precarious state with the onset of disease being highly dependent on factors which exacerbate or moderate autoimmune destruction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832597      PMCID: PMC1535623          DOI: 10.1111/j.1365-2249.1991.tb05750.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice.

Authors:  R Yasunami; J F Bach
Journal:  Eur J Immunol       Date:  1988-03       Impact factor: 5.532

2.  The presence of splenic T cells specific for islet cell antigens in nonobese diabetic mice.

Authors:  M Nagata; K Yokono; N Hatamori; K Shii; S Baba
Journal:  Clin Immunol Immunopathol       Date:  1989-11

Review 3.  Evidence for a critical role of diet in the development of insulin-dependent diabetes mellitus.

Authors:  F W Scott; D Daneman; J M Martin
Journal:  Diabetes Res       Date:  1988-04

4.  An explanation for the protective effect of the MHC class II I-E molecule in murine diabetes.

Authors:  E P Reich; R S Sherwin; O Kanagawa; C A Janeway
Journal:  Nature       Date:  1989-09-28       Impact factor: 49.962

5.  Association of beta-cell-specific expression of endogenous retrovirus with development of insulitis and diabetes in NOD mouse.

Authors:  K Suenaga; J W Yoon
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

6.  Prevention of type I diabetes in nonobese diabetic mice by virus infection.

Authors:  M B Oldstone
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

7.  Dietary prevention of diabetes in the non-obese diabetic mouse.

Authors:  R B Elliott; S N Reddy; N J Bibby; K Kida
Journal:  Diabetologia       Date:  1988-01       Impact factor: 10.122

8.  Prevention of diabetes in NOD mice by injection of autoreactive T-lymphocytes.

Authors:  E P Reich; D Scaringe; J Yagi; R S Sherwin; C A Janeway
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

9.  Comparison of high- and low-diabetes-incidence NOD mouse strains.

Authors:  A G Baxter; M A Adams; T E Mandel
Journal:  Diabetes       Date:  1989-10       Impact factor: 9.461

10.  Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus.

Authors:  B Charlton; A Bacelj; R M Slattery; T E Mandel
Journal:  Diabetes       Date:  1989-04       Impact factor: 9.461

View more
  5 in total

1.  In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes.

Authors:  Daniel J Moore; Jozef Zienkiewicz; Peggy L Kendall; Danya Liu; Xueyan Liu; Ruth Ann Veach; Robert D Collins; Jacek Hawiger
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

Review 2.  Mechanisms of diabetic autoimmunity: I--the inductive interface between islets and the immune system at onset of inflammation.

Authors:  Nadir Askenasy
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model.

Authors:  Xian Zhou; Shijie Zhang; Fan Yu; Gan Zhao; Shuang Geng; Wencong Yu; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2019-10-23       Impact factor: 3.452

4.  Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model.

Authors:  John Virostko; Armandla Radhika; Greg Poffenberger; Adrienne N Dula; Daniel J Moore; Alvin C Powers
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

5.  The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.

Authors:  Helena Cucak; Gitte Hansen; Niels Vrang; Torben Skarsfeldt; Eva Steiness; Jacob Jelsing
Journal:  J Diabetes Res       Date:  2016-02-03       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.